NewsRx

Search our medical news database

DNA Research

Study results from L. Ding et al provide new insights into DNA research

Published in Cancer Weekly, August 4th, 2009

"Camptothecin (CPT) reversibly binds and stabilizes cleavable complexes formed between DNA and topoisomerase I (Topl), thereby activating many downstream signaling pathways. Although several pathways induced by CPT have been elucidated, there are additional proteins that represent targets of CPT pharmacological mechanisms and remain uncharacterized," researchers in Shanghai, People's Republic of China report.

"Using two-dimensional electrophoresis analysis and matrix assisted laser desorption/ionization-time of flight (MALDI-TOF)-MS/MS identification, we investigated the hepatocellular carcinoma cell line SMMC-7721 for changes of protein expression following CPT...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook